Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP11B2 | P19099 | 1/20 | 0.54 |
| ▸ | SCD5 | Q86SK9 | 2/20 | 0.51 |
| ▸ | SCD | O00767 | 1/20 | 0.51 |
| ▸ | HSD11B1 | P28845 | 2/20 | 0.50 |
| ▸ | NAMPT | P43490 | 1/20 | 0.48 |
| ▸ | SPR | P35270 | 1/20 | 0.48 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.48 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.46 |
| ▸ | BLM | P54132 | 1/20 | 0.46 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | HPGD | P15428 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15529997 | 0.85 | NAMPT (0.62) | NAMPTGRIN2BLMNA | |
| SCHEMBL14970361 | 0.85 | CYP11B2 (0.53) | CYP11B2SCD5SCDHSD11B1NAMPT | |
| SCHEMBL5901385 | 0.84 | HSD11B1 (0.57) | CYP11B2SCD5SCDHSD11B1NAMPT | |
| SCHEMBL15492435 | 0.81 | CYP11B2 (0.49) | CYP11B2SCD5SCDHSD11B1NAMPT | |
| SCHEMBL16219016 | 0.81 | CYP11B2 (0.49) | CYP11B2SCD5SCDHSD11B1NAMPT | |
| SCHEMBL13194707 | 0.81 | CYP11B2 (0.49) | CYP11B2SCD5SCDHSD11B1NAMPT | |
| SCHEMBL21828566 | 0.81 | NAMPT (0.46) | CYP11B2SCD5SCDHSD11B1NAMPT | |
| SCHEMBL3719998 | 0.80 | HDAC4 (0.40) | SCD5SCDHSD11B1SPRGRIN2B | |
| SCHEMBL31703460 | 0.80 | RAB9A (0.51) | SCD5SCDGRIN2BALDH1A1HPGD | |
| SCHEMBL15529611 | 0.79 | NAMPT (0.56) | NAMPTGRIN2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220213061-A9 | HETEROCYCLIC COMPOUNDS FOR MODULATING NR2F6 | TES PHARMA S.R.L. (IT) | 2022-07-07 | — | — | US | disclosed |
| US-20210323942-A1 | HETEROCYCLIC COMPOUNDS FOR MODULATING NR2F6 | TES PHARMA S R L (IT) | 2021-10-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220213061-A9 | HETEROCYCLIC COMPOUNDS FOR MODULATING NR2F6 | NR2E3, NR2F2, NR2C2 | CYP11B2 751/4885SCD5 4313/4885SCD 3381/4885 |
| US-20210323942-A1 | HETEROCYCLIC COMPOUNDS FOR MODULATING NR2F6 | NR2E3, NR2F2, NR2C2 | CYP11B2 751/4885SCD5 4313/4885SCD 3381/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.